ADVANCED CANCER

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This study explores whether growing miniature versions of a patient's own pancreatic tumor in the lab (called organoids) can help doctors choose the most effective drug for that individual. About 25 adults with advanced, inoperable pancreatic cancer will have their tumor organoid…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study tests a combination of three drugs (177Lu girentuximab, cabozantinib, and nivolumab) in people with advanced clear cell kidney cancer who have not had prior treatment. The goal is to see if the combination can control the cancer and to check for side effects. About 100…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tu…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is …

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase study tests a new oral drug, TQB3122, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow disease. About 86 adults aged 18-75 wi…

This study tests a treatment for people with advanced bile duct cancer (ICC) that cannot be removed by surgery. The treatment combines chemotherapy given directly into the liver (HAIC) with immunotherapy drugs. The goal is to see if this combination can shrink tumors enough to al…

This study tests whether using chemotherapy alone before surgery works as well as chemotherapy followed by radiation for people with locally advanced rectal cancer. About 540 adults with stage T3 or node-positive rectal cancer will take part. The goal is to see if avoiding radiat…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This study is tracking 800 Chinese patients with advanced HER2-positive or HER2-low breast cancer who are receiving trastuzumab deruxtecan (T-DXd) in real-world clinics. Researchers want to see how long patients stay on treatment and how well it works outside of clinical trials. …

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…

This early-stage trial is testing an experimental drug called RBS2418, taken as a pill, to see if it can help the immune system fight advanced cancers that have spread or come back. The study involves 164 adults with various solid tumors who have already tried standard treatments…

This study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…

This study offers people with advanced or rare cancers a personalized treatment plan based on their tumor's genetic profile. Each participant receives a unique therapy chosen by a team of experts. The goal is to see if these tailored treatments can shrink tumors and help more pat…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-stage study tests a new drug, TQB3002, in 150 adults with advanced cancers that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and look …

This study tests an inhaled treatment called KB707, a modified herpes virus designed to trigger the immune system against lung tumors. It is for adults with advanced solid tumors that have spread to the lungs and who have run out of standard options. The trial will test KB707 alo…

This study offers continued access to the cancer drug T-DXd for up to 50 people with advanced or metastatic cancer who are already benefiting from it in earlier trials. Researchers will monitor long-term safety, including serious side effects and reasons for stopping or reducing …

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participant…

This study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…

This phase 3 trial tests whether taking olanzapine and metoclopramide together can prevent nausea and vomiting caused by strong opioid painkillers in adults with advanced cancer. About 222 participants will either receive the drug combination or no preventive treatment for 7 days…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This study tests a program called BOLSTER, which offers six telehealth sessions with a nurse to help patients with advanced gynecologic or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Participants also get access to a w…

This pilot study tests whether a new, faster radiation planning method can safely ease severe abdominal pain caused by advanced cancer. Instead of a separate planning session, doctors use existing scans to create a treatment plan on the spot. Only 5 people will take part, and the…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study tests two types of spiritual care for people with advanced cancer. Researchers want to see if these programs improve spiritual well-being and reduce hospital visits. About 288 patients from religious communities will take part.

This study looks at whether asking people with advanced cancer about their financial struggles each month can help reduce their worry and improve their quality of life. About 1,000 adults receiving treatment for advanced or metastatic cancer will be randomly assigned to either mo…

This study tests a program called ENABLE-SG, which provides phone-based coaching sessions to people recently diagnosed with advanced cancer and their caregivers. The goal is to help them manage stress, symptoms, and planning early on, rather than waiting for a crisis. Researchers…

This study compares two approaches to early palliative care for people with advanced cancer. In one group, everyone gets a referral to palliative care. In the other, referrals happen only when patients report moderate-to-severe symptoms through an online screening tool. The goal …

This pilot study tests a program called SONATA that helps older adults (65+) with advanced cancer strengthen their social connections. The program includes goal-setting, mapping out one's support network, and improving communication with loved ones. Researchers want to see if the…

This pilot study tests a spiritual care program called PEACE, led by chaplains and clinicians, for people with advanced cancer. The goal is to see if it helps patients whose faith influences their medical decisions. Sixty participants will receive two counseling sessions or usual…

This pilot study tests two types of spiritual care for Black patients with advanced cancer. Researchers want to see if these interventions improve spiritual well-being and readiness to make future care plans. The study will enroll 64 participants from outpatient clinics to see if…

This study tests whether electronic surveys can help people with advanced cancer report their symptoms and care needs, so their doctors can connect them to palliative (supportive) care services sooner. About 90 adults with incurable solid tumors will participate. The goal is to s…

This study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and …

This study tests whether a care coach-led team that combines palliative care and rehabilitation can improve quality of life for 770 adults with advanced cancer who are having major surgery. The program addresses physical, emotional, and functional needs before and after surgery. …

This study tests whether modafinil, a drug that promotes wakefulness, can reduce severe fatigue and thinking problems in people with advanced cancer. About 40 adults with stage III or IV cancer will receive either modafinil or a placebo for a short time. The goal is to see if the…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…

This study tests four treatments—haloperidol, chlorpromazine, valproic acid, and a placebo—given through an IV to help calm agitated delirium in hospitalized cancer patients. The goal is to find which option works best to reduce distress and improve comfort. About 42 adults with …

This study tests a practical geriatric assessment (PGA) for adults aged 70+ with advanced cancer. The PGA is a questionnaire completed before a doctor visit, and results are shared with the care team to help guide chemotherapy dosing. Researchers will also track step counts with …

This observational study tracks over 10,000 people with advanced or metastatic cancer to understand why outcomes vary by race and background. Researchers collect social, genetic, and treatment data from patients at four cancer centers. The goal is to identify factors—like social …

This study looks at how cancer treatments can cause nerve pain. Researchers will use simple tests, like checking how you feel heat, cold, and touch, along with small skin samples, to understand why this pain happens. The goal is to find better ways to measure and eventually treat…

This study tests a program called ALIGN, which uses palliative care social workers and patient navigators to support older adults with advanced cancer who are moving from the hospital to a skilled nursing facility. The goal is to see if the program is practical and can help align…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study looks at how SPECT imaging can help doctors measure the amount of radiation reaching healthy organs during certain cancer treatments. About 80 adults with advanced prostate or other cancers will get extra SPECT scans before and after their standard radiation therapy. T…

This study looks at how healthcare providers and caregivers perceive discomfort in advanced cancer patients who have hypoactive delirium, a state where patients are unresponsive and withdrawn. Researchers will ask both groups to fill out questionnaires about the patient's discomf…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study tests whether a Personalized Therapeutics Clinic (PTC) can lower the risk of harmful drug interactions in cancer patients. Participants get genetic testing to see how their medications interact with each other and with their genes. The goal is to help doctors prescribe…

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…